FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3034594034> ?p ?o ?g. }

• W3034594034 endingPage "1424" @default.
• W3034594034 startingPage "1415" @default.
• W3034594034 abstract "•HVPG ≥10 mmHg persists 2 years after therapy in 53–65% of patients with HCV-related cirrhosis despite HCV eradication. •Changes in liver stiffness do not correlate with changes in HVPG after a sustained virological response. •Baseline HVPG ≥16 mmHg and ascites identify patients with persistent CSPH and risk of decompensation. Background & Aims Clinically significant portal hypertension (CSPH), defined as a hepatic venous pressure gradient (HVPG) ≥10 mmHg, persists 24 weeks after sustained virological response (SVR) in up to 78% of patients with HCV-related cirrhosis treated with direct-acting antivirals. These patients remain at risk of decompensation. However, long-term paired clinical and hemodynamic data are not available for this population. Methods We conducted a prospective multicenter study in 226 patients with HCV-related cirrhosis and CSPH who achieved SVR after antiviral therapy. Patients with CSPH 24 weeks after end of treatment (SVR24) were offered another hemodynamic assessment 96 weeks after end of treatment (SVR96). Results All patients were clinically evaluated. Out of 176 patients with CSPH at SVR24, 117 (66%) underwent an HVPG measurement at SVR96. At SVR96, 55/117 (47%) patients had HVPG <10 mmHg and 53% had CSPH (65% if we assume persistence of CSPH in all 59 non-evaluated patients). The proportion of high-risk patients (HVPG ≥16 mmHg) diminished from 41% to 15%. Liver stiffness decreased markedly after SVR (median decrease 10.5 ± 13 kPa) but did not correlate with HVPG changes (30% of patients with liver stiffness measurement <13.6 kPa still had CSPH). Seventeen (7%) patients presented with de novo/additional clinical decompensation, which was independently associated with baseline HVPG ≥16 mmHg and history of ascites. Conclusions Patients achieving SVR experienced a progressive reduction in portal pressure during follow-up. However, CSPH may persist in up to 53–65% of patients at SVR96, indicating persistent risk of decompensation. History of ascites and high-risk HVPG values identified patients at higher risk of de novo or further clinical decompensation. Lay summary As a major complication of cirrhosis, clinically significant portal hypertension (CSPH) is associated with adverse clinical outcomes. Herein, we show that CSPH persists at 96 weeks in just over half of patients with HCV-related cirrhosis, despite HCV elimination by direct-acting antivirals. Despite viral cure, patients with CSPH at the start of antiviral treatment remain at long-term risk of hepatic complications and should be managed accordingly. Clinically significant portal hypertension (CSPH), defined as a hepatic venous pressure gradient (HVPG) ≥10 mmHg, persists 24 weeks after sustained virological response (SVR) in up to 78% of patients with HCV-related cirrhosis treated with direct-acting antivirals. These patients remain at risk of decompensation. However, long-term paired clinical and hemodynamic data are not available for this population. We conducted a prospective multicenter study in 226 patients with HCV-related cirrhosis and CSPH who achieved SVR after antiviral therapy. Patients with CSPH 24 weeks after end of treatment (SVR24) were offered another hemodynamic assessment 96 weeks after end of treatment (SVR96). All patients were clinically evaluated. Out of 176 patients with CSPH at SVR24, 117 (66%) underwent an HVPG measurement at SVR96. At SVR96, 55/117 (47%) patients had HVPG <10 mmHg and 53% had CSPH (65% if we assume persistence of CSPH in all 59 non-evaluated patients). The proportion of high-risk patients (HVPG ≥16 mmHg) diminished from 41% to 15%. Liver stiffness decreased markedly after SVR (median decrease 10.5 ± 13 kPa) but did not correlate with HVPG changes (30% of patients with liver stiffness measurement <13.6 kPa still had CSPH). Seventeen (7%) patients presented with de novo/additional clinical decompensation, which was independently associated with baseline HVPG ≥16 mmHg and history of ascites. Patients achieving SVR experienced a progressive reduction in portal pressure during follow-up. However, CSPH may persist in up to 53–65% of patients at SVR96, indicating persistent risk of decompensation. History of ascites and high-risk HVPG values identified patients at higher risk of de novo or further clinical decompensation." @default.
• W3034594034 created "2020-06-19" @default.
• W3034594034 creator A5016951290 @default.
• W3034594034 creator A5017803053 @default.
• W3034594034 creator A5030278672 @default.
• W3034594034 creator A5031903041 @default.
• W3034594034 creator A5033243852 @default.
• W3034594034 creator A5034063053 @default.
• W3034594034 creator A5035633963 @default.
• W3034594034 creator A5036505681 @default.
• W3034594034 creator A5037927976 @default.
• W3034594034 creator A5041306394 @default.
• W3034594034 creator A5044930988 @default.
• W3034594034 creator A5048913916 @default.
• W3034594034 creator A5050130370 @default.
• W3034594034 creator A5054502364 @default.
• W3034594034 creator A5054601700 @default.
• W3034594034 creator A5070198508 @default.
• W3034594034 creator A5072599627 @default.
• W3034594034 creator A5075817412 @default.
• W3034594034 creator A5077891286 @default.
• W3034594034 creator A5091651183 @default.
• W3034594034 date "2020-12-01" @default.
• W3034594034 modified "2023-10-17" @default.
• W3034594034 title "Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension" @default.
• W3034594034 cites W1964051982 @default.
• W3034594034 cites W1978304182 @default.
• W3034594034 cites W1980154502 @default.
• W3034594034 cites W1982878947 @default.
• W3034594034 cites W1988986320 @default.
• W3034594034 cites W1993383522 @default.
• W3034594034 cites W2016340416 @default.
• W3034594034 cites W2024795971 @default.
• W3034594034 cites W2066984664 @default.
• W3034594034 cites W2101099470 @default.
• W3034594034 cites W2149727669 @default.
• W3034594034 cites W2277004004 @default.
• W3034594034 cites W2406748516 @default.
• W3034594034 cites W2540370990 @default.
• W3034594034 cites W2557228144 @default.
• W3034594034 cites W2592390364 @default.
• W3034594034 cites W2736841222 @default.
• W3034594034 cites W2748400966 @default.
• W3034594034 cites W2807735287 @default.
• W3034594034 cites W2809950681 @default.
• W3034594034 cites W2913385034 @default.
• W3034594034 cites W2922822790 @default.
• W3034594034 cites W2964678848 @default.
• W3034594034 doi "https://doi.org/10.1016/j.jhep.2020.05.050" @default.
• W3034594034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32535060" @default.
• W3034594034 hasPublicationYear "2020" @default.
• W3034594034 type Work @default.
• W3034594034 sameAs 3034594034 @default.
• W3034594034 citedByCount "91" @default.
• W3034594034 countsByYear W30345940342020 @default.
• W3034594034 countsByYear W30345940342021 @default.
• W3034594034 countsByYear W30345940342022 @default.
• W3034594034 countsByYear W30345940342023 @default.
• W3034594034 crossrefType "journal-article" @default.
• W3034594034 hasAuthorship W3034594034A5016951290 @default.
• W3034594034 hasAuthorship W3034594034A5017803053 @default.
• W3034594034 hasAuthorship W3034594034A5030278672 @default.
• W3034594034 hasAuthorship W3034594034A5031903041 @default.
• W3034594034 hasAuthorship W3034594034A5033243852 @default.
• W3034594034 hasAuthorship W3034594034A5034063053 @default.
• W3034594034 hasAuthorship W3034594034A5035633963 @default.
• W3034594034 hasAuthorship W3034594034A5036505681 @default.
• W3034594034 hasAuthorship W3034594034A5037927976 @default.
• W3034594034 hasAuthorship W3034594034A5041306394 @default.
• W3034594034 hasAuthorship W3034594034A5044930988 @default.
• W3034594034 hasAuthorship W3034594034A5048913916 @default.
• W3034594034 hasAuthorship W3034594034A5050130370 @default.
• W3034594034 hasAuthorship W3034594034A5054502364 @default.
• W3034594034 hasAuthorship W3034594034A5054601700 @default.
• W3034594034 hasAuthorship W3034594034A5070198508 @default.
• W3034594034 hasAuthorship W3034594034A5072599627 @default.
• W3034594034 hasAuthorship W3034594034A5075817412 @default.
• W3034594034 hasAuthorship W3034594034A5077891286 @default.
• W3034594034 hasAuthorship W3034594034A5091651183 @default.
• W3034594034 hasConcept C126322002 @default.
• W3034594034 hasConcept C164705383 @default.
• W3034594034 hasConcept C178853913 @default.
• W3034594034 hasConcept C2777214474 @default.
• W3034594034 hasConcept C2778721985 @default.
• W3034594034 hasConcept C2778808290 @default.
• W3034594034 hasConcept C2780496750 @default.
• W3034594034 hasConcept C2908647359 @default.
• W3034594034 hasConcept C56900294 @default.
• W3034594034 hasConcept C71924100 @default.
• W3034594034 hasConcept C90924648 @default.
• W3034594034 hasConcept C99454951 @default.
• W3034594034 hasConceptScore W3034594034C126322002 @default.
• W3034594034 hasConceptScore W3034594034C164705383 @default.
• W3034594034 hasConceptScore W3034594034C178853913 @default.
• W3034594034 hasConceptScore W3034594034C2777214474 @default.
• W3034594034 hasConceptScore W3034594034C2778721985 @default.
• W3034594034 hasConceptScore W3034594034C2778808290 @default.
• W3034594034 hasConceptScore W3034594034C2780496750 @default.

• next